List of figures

Figure

1: Age sex distribution of tuberculosis prevalence in the ICMR sample survey 1955 – 58 ................. 9
2: Age sex distribution of tuberculosis prevalence in India between 1950 and 1978 as reported by various studies ........................................................................................................................................... 10
3: Trend of age sex distribution of tuberculosis prevalence in India between 1981 and 2004 as reported by various studies ........................................................................................................................................... 11
4: Age sex distribution of tuberculosis prevalence in tribal population in India as reported by various studies ........................................................................................................................................... 12
5: Diagnostic protocol used in RNTCP ........................................................................................................... 25
6: RNTCP treatment card front (a) and rear view(b) ........................................................................... 28
7: Tuberculosis units in Pune city .................................................................................................................. 29
8: Recruitment of study participants ........................................................................................................... 30
9: Questionnaires relevant to tuberculosis in Standard verbal autopsy questionnaire ....................... 39
10: Modified RNTCP treatment card after incorporating predictive tool .............................................. 42
11: Age and sex distribution of tuberculosis patients ...................................................................................... 48
12: Distribution of patients engaged in migration prone occupation by TU ........................................... 53
13: Survival of patients by age groups at six months after initiation of DOTS ......................................... 57
14: Survival of patients by age groups at twelve months after initiation of DOTS ..................................... 57
15: Survival of patients by age groups at eighteen months after initiation of DOTS .............................. 58
16: Survival of male and female patients at 6 months after initiation of DOTS ........................................... 59
17: Survival of male and female patients at 12 months after initiation of DOTS ............................................ 60
18: Survival of male and female patients at 18 months after initiation of DOTS ......................................... 60
19: Survival of patients based on type of case at 6 months after initiation of DOTS ................................. 62
20: Survival of patients based on type of case at 12 months after initiation of DOTS ............................... 62
21: Survival of patients based on type of case at 18 months after initiation of DOTS ............................... 63
22: Survival of patients based on baseline sputum status at 6 months after initiation of DOTS ............. 64
23: Survival of patients based on baseline sputum status at 12 months after initiation of DOTS ............ 65
24: Survival of patients based on baseline sputum status at 18 months after initiation of DOTS ............ 65
25: Survival of patients based on treatment outcome at 6 months after initiation of DOTS ................. 67
26: Survival of patients based on treatment outcome at 12 months after initiation of DOTS ................. 67
27: Survival of patients based on treatment outcome at 18 months after initiation of DOTS ................. 68
28: Survival of patients based on HIV status at 6 months after initiation of DOTS ................................. 70
29: Survival of patients based on HIV status at 12 months after initiation of DOTS ............................... 70
30: Survival of patients based on HIV status at 18 months after initiation of DOTS ............................... 71
31: Survival of patients based on presence of co morbidity (DM) at 6 months after initiation of DOTS .. 73
32: Survival of patients based on presence of co morbidity (DM) at 12 months after initiation of DOTS .... 73
33: Survival of patients based on presence of co morbidity (DM) at 18 months after initiation of DOTS .... 74
34: Hazard function for female patients with tuberculosis at 18 months after initiation of DOTS .. 81
35: Age and sex distribution of a) SMR and b) CFR .............................................................................. 86
36: Risks for mortality among women patients based on information identified in the study ............. 125